784 related articles for article (PubMed ID: 25843416)
21. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
22. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
23. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
[TBL] [Abstract][Full Text] [Related]
24. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.
Bari A; Marcheselli L; Sacchi S; Marcheselli R; Pozzi S; Ferri P; Balleari E; Musto P; Neri S; Aloe Spiriti MA; Cox MC
Ann Oncol; 2010 Jul; 21(7):1486-1491. PubMed ID: 19920060
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Cancer Sci; 2012 Oct; 103(10):1898-904. PubMed ID: 22783941
[TBL] [Abstract][Full Text] [Related]
26. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
[TBL] [Abstract][Full Text] [Related]
28. Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma.
Aoki T; Nishiyama T; Imahashi N; Kitamura K
Ann Hematol; 2012 Mar; 91(3):375-82. PubMed ID: 21811783
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
[TBL] [Abstract][Full Text] [Related]
30. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
[TBL] [Abstract][Full Text] [Related]
31. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
32. Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma.
Shimono J; Takahashi S; Takemura R; Kakinoki Y
Int J Lab Hematol; 2019 Dec; 41(6):754-761. PubMed ID: 31529774
[TBL] [Abstract][Full Text] [Related]
33. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
[TBL] [Abstract][Full Text] [Related]
34. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
35. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy.
Hassan U; Ishtiaq S; Hussain M
J Coll Physicians Surg Pak; 2014 Oct; 24(10):722-7. PubMed ID: 25327914
[TBL] [Abstract][Full Text] [Related]
37. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and prognostic analysis of 98 cases of relapsed/refractory diffuse large B-cell lymphoma treated with second-line regimens].
Zhang MC; Qian Y; Hao J; Liu ZY; Zhao WL; Wang L
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):511-516. PubMed ID: 28655095
[No Abstract] [Full Text] [Related]
39. Absolute Monocyte and Platelet Counts May Provide Additional Prognostic Information in Primary Gastric Diffuse Large B-cell Lymphoma Patients Treated with Rituximab and CHOP.
Spassov B; Vassileva D; Nikolov S; Ganeva P; Balatzenko G; Guenova M
Folia Med (Plovdiv); 2020 Dec; 62(4):785-801. PubMed ID: 33415923
[TBL] [Abstract][Full Text] [Related]
40. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
